

IFW



PATENT
ATTORNEY DOCKET NO. 50047/019002

Certificate of Mailing: Date of Deposit: September 17, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Janet D'Annunzio-Ellis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Salomon Amar et al.	Art Unit:	1653
Serial No.:	10/796,947	Examiner:	Not Yet Assigned
Filed:	March 10, 2004	Customer No.:	21559
Title:	NOVEL LITAF BINDING SITE PEPTIDES AND METHODS OF USING THE SAME		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.


If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

Sept. 17, 2004



Paul T. Clark

Registration No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449
(MOBILE)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50047/019002

Serial No.

10/796,947

Applicant

Amar et al.

Filing Date

March 10, 2004

Group

1653

IDS Filed

September 17, 2004

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	6,566,501	5/20/03	Amar	530	350	4/12/00

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281(5381):1322-1326 (1998).
	Alexander et al., "Treatment with Recombinant Human Tumor Necrosis Factor-Alpha Protects Rats Against the Lethality, Hypotension, and Hypothermia of Gram-Negative Sepsis," <i>J. Clin. Invest.</i> , 88:34-39 (1991).
	Amar and Han, "Regulation of tumour necrosis factor- α gene expression," <i>Appl. Genomics Proteomics</i> 1(1):31-44 (2002).
	Beutler and Cerami, "The Biology of Cachectin/TNF—A Primary Mediator of the Host Response," <i>Ann. Rev. Immunol.</i> , 7:625-655 (1989).
	Brugarolas et al., "Radiation-induced cell cycle arrest compromised by p21 deficiency," <i>Nature</i> , 377(6549):552-557 (1995).
	Capecchi, M.R., "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," <i>Cell</i> , 22(2 Pt. 2):479-488 (1980).
	Cepko et al., "Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector," <i>Cell</i> , 37(3):1053-1062 (1984).
	Donis-Keller, H., "Phy M: an RNase activity specific for U and A residues useful in RNA sequence analysis," <i>Nucleic Acids Res.</i> , 8(14):3133-3142 (1980).
	Drouet et al., "Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor- α promoter in primary macrophages," <i>J. Immunol.</i> , 147(5):1694-1700 (1991).
	Ei-Deiry et al., "WAF1, A Potential Mediator of p53 Tumor Suppression," <i>Cell</i> , 75(4):817-825 (1993).
	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," <i>Pro. Natl. Acad. Sci. USA</i> , 84:7413-7417 (1987).
	Galas and Schmitz, "DNAase footprinting: a simple method for the detection of protein-DNA binding specificity," <i>Nucleic Acids Res.</i> , 5(9):3157-3170 (1978).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50047/019002 Serial No. 10/796,947 Applicant Amar et al. Filing Date March 10, 2004 Group 1653 IDS Filed September 17, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," <i>Virology</i> , 52(2):456-467 (1973).					
	Horng et al., "TIRAP: an adapter molecule in the Toll signaling pathway," <i>Nat. Immunol.</i> , 2(9):835-841 (2001).					
	IUPAC Commission on the Nomenclature of Organic Chemistry and IUPAC-IUB Commission on Biochemical Nomenclature, "Nomenclature of α -Amino Acids (Recommendations, 1974)," <i>Biochemistry</i> 14(2):449-462 (1975).					
	Kinzler and Vogelstein, "Life (and death) in a malignant tumour," <i>Nature</i> , 379(6560):19-20 (1996).					
	Ko and Prives, "p53: puzzle and paradigm," <i>Genes & Dev.</i> , 10(9):1054-1072 (1996).					
	Ksontini et al., "Disparate Roles for TNF- α and Fas Ligand in Concanavalin A-Induced Hepatitis," <i>J. Immunol.</i> , 160:4082-4089 (1998).					
	Levine, A.J., "p53, the Cellular Gatekeeper for Growth and Division," <i>Cell</i> , 88(3):323-331 (1997).					
	Li et al., "Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53," <i>Proc. Natl. Acad. Sci. USA</i> , 99(16):10364-10369 (2002).					
	McClane et al., "Functional Consequences of Adenovirus-Mediated Murine Pancreatic Gene Transfer," <i>Hum. Gene Ther.</i> , 8(6):739-746 (1997).					
	Miyashita and Reed, "Tumor Suppressor p53 Is a Direct Transcriptional Activator of the Human <i>Bax</i> Gene," <i>Cell</i> , 80(2):293-299 (1995).					
	Morris et al., "A peptide carrier for the delivery of biologically active proteins into mammalian cells," <i>Nat. Biotechnol.</i> , 19(12):1173-1176 (2001).					
	Munshi et al., "Lipopolysaccharide-Induced Apoptosis of Endothelial Cells and Its Inhibition by Vascular Endothelial Growth Factor," <i>J. Immunol.</i> , 168(11):5860-5866 (2002).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50047/019002 Serial No. 10/796,947 Applicant Amar et al. Filing Date March 10, 2004 Group 1653 IDS Filed September 17, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Myokai et al., "A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor α gene expression: Molecular cloning, sequencing, characterization, and chromosomal assignment," <i>Proc. Natl. Acad. Sci. USA</i> , 96:4518-4523 (1999).					
	Neumann et al., "Gene transfer into mouse lyoma cells by electroporation in high electric fields," <i>EMBO J.</i> , 1(7):841-845 (1982).					
	Polyak et al., "A model for p53-induced apoptosis," <i>Nature</i> , 389(6648):300-305 (1997).					
	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> 2:482-489(1981).					
	Suganuma et al., "A New Process Of Cancer Prevention Mediated Through Inhibitor Of Tumor Necrosis Factor α Expression," <i>Cancer Res.</i> , 56(16):3711-3715 (1996).					
	Sugarman et al., "Recombinant Human Tumor Necrosis Factor- α : Effects on Proliferation of Normal and Transformed Cells in Vitro," <i>Science</i> , 230(4728):943-945 (1985).					
	Talmadge et al., "Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor," <i>Cancer Res.</i> , 48(3):544-550 (1988).					
	Tang et al., "Identification and functional characterization of a novel binding site on TNF- α promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 100(7):4096-4101 (2003).					
	Ugliarolo et al., "Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor- α gene promoter," <i>Tissue Antigens</i> , 52(4):359-367 (1998).					
	Vousden and Lu, "Live or Let Die: The Cell's Response to p53," <i>Nat. Rev. Cancer</i> , 2(8):594-604 (2002).					
	Xaus et al., "LPS induces apoptosis in macrophages mostly through the autocrine production of TNF- α ," <i>Blood</i> , 95(12):3823-3831 (2000).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						